Complete financial analysis of VectivBio Holding AG (VECT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of VectivBio Holding AG, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Mattel, Inc. (MAT) Income Statement Analysis – Financial Results
- NVE Corporation (NVEC) Income Statement Analysis – Financial Results
- Adolfo Domínguez, S.A. (ADZ.MC) Income Statement Analysis – Financial Results
- Kindly MD, Inc. (KDLY) Income Statement Analysis – Financial Results
- Gaia Grow Corp. (GAIA.CN) Income Statement Analysis – Financial Results
VectivBio Holding AG (VECT)
About VectivBio Holding AG
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 27.34M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 27.34M | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 73.95M | 50.18M | 43.04M | 15.98M |
| General & Administrative | 33.91M | 35.81M | 14.02M | 8.23M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 33.91M | 35.81M | 14.02M | 8.23M |
| Other Expenses | 0.00 | 729.00K | 207.00K | 102.00K |
| Operating Expenses | 107.87M | 86.72M | 57.26M | 24.32M |
| Cost & Expenses | 107.87M | 86.72M | 57.26M | 24.32M |
| Interest Income | 676.00K | 0.00 | 1.00K | 15.00K |
| Interest Expense | 3.16M | 36.00K | 554.00K | 50.00K |
| Depreciation & Amortization | 676.00K | 303.00K | -293.00K | 167.00K |
| EBITDA | -79.85M | -86.41M | -57.55M | -24.15M |
| EBITDA Ratio | -292.04% | 0.00% | 0.00% | 0.00% |
| Operating Income | -80.52M | -86.72M | -57.26M | -24.32M |
| Operating Income Ratio | -294.52% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.10M | -293.00K | -2.68M | 834.00K |
| Income Before Tax | -93.63M | -86.95M | -59.94M | -23.48M |
| Income Before Tax Ratio | -342.45% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 107.00K | 64.00K | 554.00K | 50.00K |
| Net Income | -93.74M | -87.01M | -60.50M | -23.53M |
| Net Income Ratio | -342.84% | 0.00% | 0.00% | 0.00% |
| EPS | -2.12 | -3.23 | -6.30 | -1.01 |
| EPS Diluted | -2.12 | -3.23 | -6.30 | -1.01 |
| Weighted Avg Shares Out | 44.13M | 26.96M | 9.60M | 23.35M |
| Weighted Avg Shares Out (Dil) | 44.13M | 26.96M | 9.60M | 23.35M |
Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares
BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced the successful completion...
Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio
BOSTON & BASEL, Switzerland--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (“Ironwood”) (Nasdaq: IRWD), a GI-focused healthcare company, and VectivBio Holding AG (“VectivBio”) (Nasdaq: VECT), a global clinical-stage biopharmaceutical company pioneering novel, transformational treatments for severe rare gastrointestinal conditions, today announced that the waiting...
Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround
Ironwood's drug Linzess is seeing its sales start to plateau. It could get an expanded indication for Linzess that delays a decline in revenue.
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD)....
VECTIVBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of VectivBio Holding AG - VECT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of VectivBio Holding AG (NasdaqGS: VECT) to Ironwood Pharmaceuticals, Inc. (NasdaqGS: IRWD)....
Why Shares of VectivBio Holding Are Up Today
Ironwood Pharmaceuticals' buyout deal is worth $1 billion. The attraction was VectivBio's late-stage therapy, apraglutide.
VectivBio Stock Catapults 38% After Ironwood Agrees To Buy It For $1 Billion
Ironwood Pharmaceuticals said Monday it will buy VectivBio for $1 billion. The deal sent VECT stock flying, while IRWD stock skidded.
VECT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of VectivBio Holding AG Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of VectivBio Holding AG (NASDAQ: VECT) to Ironwood Pharmaceuticals, Inc. for $17.00 per share is fair to VectivBio shareholders. Halper Sadeh encourages VectivBio shareholders to...
Ironwood Pharmaceuticals to Acquire VectivBio for About $1 Billion
Ironwood Pharmaceuticals is paying $17 a share for the Swiss biotech company.
Ironwood Pharmaceuticals to acquire Swiss biotech VectivBio in deal valued at about $1 billion
Ironwood Pharmaceuticals Inc. IRWD, +2.45% said Monday it has agreed to acquire Swiss biotech VectivBio Holding AG VECT, +8.18% for $17 a share in cash, or a total of about $1 billion, net of VectivBio's cash and debt. The price...
Source: https://incomestatements.info
Category: Stock Reports